Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06311721 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
A Phase 3 study of Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer, sponsored by Amgen.
- Active
- Registry status
- Phase 3
- Development phase
- 315
- Enrollment target
- 20
- Study locations
NCT06311721 is a Phase 3 study of Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Amgen. The registered enrollment target is 315 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT06311721, a Phase 3 study of Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 315 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to compare the efficacy of ABP 234 with the pembrolizumab reference product (Keytruda®).
Conditions Studied
Interventions
- DRUG ABP 234
- DRUG Pembrolizumab (US)
- DRUG Pembrolizumab (EU)
Study Locations (20)
California
- Precision NextGen Oncology and Research Center - Beverly Hills
- TOI Clinical Research - Cerritos
- Cancer and Blood Specialty Clinic (CBSC) - Los Alamitos
- Valkyrie Clinical Trials - Los Angeles
- PIH Health Hospital - Whittier
Florida
- Millennium Oncology - Hollywood - Hollywood
- BRCR Medical Center Inc. - Tamarac
Texas
- Millennium Research and Clinical Development, LLC - Houston
- Texas Oncology, P.A - San Antonio
Buenos Aires
- Instituto de Investigaciones Clinicas Mar del Plata - Mar del Plata
- Centro de Investigacion Pergamino SA - Pergamino
Santa Fe Province
- Sanatorio Britanico De Rosario - Rosario
- Hospital Provincial del Centenario - Rosario
Illinois
- Accellacare Duly - Plainfield
Iowa
- Accellacare of McFarland - Ames
Michigan
- Detroit Clinical Research Center, PC - Farmington Hills
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2024-09-09 |
| Est. Completion | 2028-05-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06311721
The ClinicalTrials.gov registry entry for NCT06311721 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 315 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which ABP 234 is the first listed.
NCT06311721 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT06311721 about?
NCT06311721 is a clinical study titled "A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer". The primary objective of this study is to compare the efficacy of ABP 234 with the pembrolizumab reference product (Keytruda®).
What is the current status of trial NCT06311721?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 315 participants. The study started on 2024-09-09. Estimated completion is 2028-05-29.
What conditions does trial NCT06311721 study?
This clinical trial studies the following conditions: Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06311721?
The interventions under investigation include: ABP 234 (DRUG), Pembrolizumab (US) (DRUG), Pembrolizumab (EU) (DRUG).
Who is sponsoring clinical trial NCT06311721?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06311721 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Iowa, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.